Literature DB >> 35680669

Gasless endoscopic transaxillary thyroid surgery: CUSUM analysis of a single surgeon's experience from 105 preliminary procedures.

Botao Sun1, Peiting Li1,2, Rong Cong1, Di Zhou1, Zeyu Zhang1, Fada Xia3, Xinying Li1.   

Abstract

BACKGROUND: We aimed to evaluate the feasibility and oncologic safety of gasless endoscopic transaxillary thyroidectomy (TAT) in patients with thyroid diseases. Improvements in surgical techniques were also reported, and the learning curves of gasless endoscopic TAT were further studied.
METHODS: An exact 1:1 matching analysis was performed to compare the technical safety and oncologic outcomes between TAT and conventional open surgery. A questionnaire was designed to evaluate the quality of life of enrolled patients. A cumulative summation analysis was designed for the quantitative estimation of the learning curves.
RESULTS: A total of 105 consecutive patients who successfully received endoscopic TAT were retrospectively enrolled in the current study. A standard three-step working space making procedure, an approach that does not free the superficial part of the sternal head of the sternocleidomastoid muscle (SCM, NFSSH) and a "point to line to surface" en bloc procedure utilized in lobectomy with ipsilateral central neck dissection (CND), were introduced in our surgical procedures. The mean operation time in the TAT group was significantly longer than that in the conventional open group (86.9 ± 31.3 vs 44.2 ± 8.3, p < 0.001). Significant differences in the complication rate were not found between the two groups. Discomfort in the anterior neck area and SCM was relieved over time in most cases (verbal response scores (VRSs) were gradually decreased over time). The learning curves for working space making, ipsilateral thyroidectomy and the total endoscopic TAT approach were 45 cases, 25 cases and 42 cases, respectively. The operation time in the proficient group was significantly shorter than that in the learning group (67.0 ± 8.4 vs 112.3 ± 35.7, p < 0.001). VRSs in the SCM were significantly lower in the proficient group (for 1 week: 1.25 ± 0.65 vs 2.40 ± 0.63, p < 0.001; for 1 month: 0.81 ± 0.69 vs 1.81 ± 0.40, p < 0.001).
CONCLUSIONS: Gasless endoscopic TAT was safe in a cohort of patients with thyroid diseases, with satisfactory surgical outcomes and cosmetic appearance. The learning curve for endoscopic TAT was approximately 42 cases. The proficiency of the endoscopic TAT approach depended primarily on the proficiency of working space making.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cumulative summation analysis; Endoscopic thyroidectomy; Quality of life

Year:  2022        PMID: 35680669     DOI: 10.1007/s00464-022-09273-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  6 in total

Review 1.  Remote access thyroid surgery.

Authors:  Parisha Bhatia; Hossam Eldin Mohamed; Abida Kadi; Emad Kandil; Rohan R Walvekar
Journal:  Gland Surg       Date:  2015-10

2.  Safety and efficacy of surgical and endoscopic resection in the treatment of duodenal subepithelial lesions.

Authors:  Chen Li; Chengbai Liang; Xuehong Wang; Meixian Le; Deliang Liu; Yuyong Tan
Journal:  Surg Endosc       Date:  2021-09-22       Impact factor: 3.453

3.  Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means.

Authors:  Samer A Naffouje; David T Pointer; Megan A Satyadi; Pamela Hodul; Daniel A Anaya; Jose Pimiento; Mokenge Malafa; Dae Won Kim; Jason B Fleming; Jason W Denbo
Journal:  Surg Endosc       Date:  2021-12-02       Impact factor: 3.453

Review 4.  Extracervical Approaches to Thyroid Surgery: Evolution and Review.

Authors:  B M Sephton
Journal:  Minim Invasive Surg       Date:  2019-08-20

5.  Continuous Renal Replacement Therapy (CRRT) in Children and the Specialized CRRT Team: A 14-Year Single-Center Study.

Authors:  Keum Hwa Lee; In Suk Sol; Jung Tak Park; Ji Hong Kim; Jae Won Shin; Mi Rireu Park; Jae Hyun Lee; Yoon Hee Kim; Kyung Won Kim; Jae Il Shin
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.